Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Grunenthal CEO Claims German Reimbursement Hurdle Is Fair, As Pain Drug Palexia Rolls Out Across Europe

Executive Summary

German reimbursement authority’s strong emphasis on drugs’ added benefit is logical, opines Grunenthal CEO Harald Stock. And all health care systems will eventually move the same way.


Related Content

Germany's Stada Strengthens Central, Eastern European Focus With Brand, Generic Buys
AstraZeneca’s Real-World Outcomes Deal With IMS Aims To Turn Treatment Data Into Business Decisions
Intermune’s Esbriet Flops In Front Of IQWiG
AZ’s Brilinta Is First Drug To Clear AMNOG Assessment, While Merck’s Victrelis Limps Forward
No Abuse-Resistance Claim For Endo’s Opana ER Reformulation
InterMune Launches Esbriet in Germany At Better-Than-Expected Price
J&J Wins Nucynta ER Approval, Targets Chronic Pain Market
New German Reimbursement Process Splits Opinion Ahead Of First Assessments
Novel Pain Therapeutics: When Will Life Get Better On The Island Of Pain?
Private Grünenthal Aims For Leadership In Pain


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts